Viking Therapeutics (VKTX) 2025 Conference June 05, 2025 11:40 AM ET Speaker0 Alright. Welcome, everyone, to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Song, one of the senior analysts cover SimiCAP Biotech in The US. It is my pleasure to introduce our next printing company, Viking Therapeutics CEO, Brian Lian. So he will do a corporate presentation. And if you have some time for q and a toward the end, we'll do that. Welcome, Lian. Speaker1 Great. Thanks, Roger. And thanks ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

If you'd like to learn more about how to best position yourself in undervalued stocks mispriced by the market to end May, consider joining Out Fox The Street .Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in VKTX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...

Viking Therapeutics (NASDAQ: VKTX ) is a reasonably de-risked high potential play in obesity treatments. The play is de-risked because early vetting of endocrine and metabolic therapeutics is positive. Although biotechnology bets are subject to binary outcomes, sometimes even as late asI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth invest ...

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (VKTX 3.61%) stock on Friday, which closed the trading session 3% higher. That figure was well higher than the 0.7% increase of the benchmark S&P 500 index.What's new at NovoThat rival is Novo Nordisk, which announced that its current CEO Lars Jørgensen is to vacate his position. This is the Denmark-based pharmaceutical company that vaulted to prominence earlier this decade when its Wegovy became the fi ...

文章核心观点 - 生物技术公司Viking Therapeutics因开发的减肥药受关注本周股价上涨近18%，世界卫生组织将支持肥胖药物使用，公司药物VK2735若获批有望接近Zepbound和Wegovy的受欢迎程度，且减肥药市场是全球性的 [1][2][5][6] 公司情况 - Viking Therapeutics本周股价在过去五个交易日上涨近18% [1] - Viking Therapeutics的VK2735在2期临床试验中表现出色，若获批上市有望接近Zepbound和Wegovy的受欢迎程度 [5] 行业动态 - 路透社报道世界卫生组织将支持成人使用肥胖药物，并推动改善中低收入患者获取药物的途径 [2] - 美国专门用于减肥的药物以诺和诺德的Wegovy和礼来的Zepbound为首，因比节食和锻炼更容易减肥而受公众欢迎 [4] - 因Wegovy和Zepbound的成功，制药和生物技术公司竞相开发自己的减肥药 [5] - 体重管理不仅是美国的难题，减肥药在全球都有市场 [6]

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor. That's what investors are hoping for from Viking Therapeutics (VKTX -0.66%), a young company seeking to establish itse ...

Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.Should you steer clear of Viking Therapeutics? My view is that despite its struggles this year, there's still significant upside. Let's find out why it could be a top stock to hold for the long term.Why Viking Therapeutics' shar ...

Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.Shares of Viking Therapeutics (VKTX 10.83%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.Viking stock inched higher Monday after Truist Securities analyst Joon Lee lowered his price target, while predicting the company will benefit from phase 3 clinical trial news on its new VK2735 weigh loss drug. Today, the shares are advancing by leaps and bounds on an even more ...

文章核心观点 2025年是判断Viking Therapeutics股票是否成功的一年 公司虽面临肥胖领域竞争但开展新药3期临床试验有望带来积极成果 不过目前仍是投机性股票 [1][2][5] 公司情况 - Truist Securities分析师Joon Lee将Viking Therapeutics无盈利生物科技股目标价从每股95美元降至75美元 警告公司面临肥胖领域竞争加剧 [1] - 2025年公司将开启新GLP - 1肥胖药物VK2735的3期临床试验 若试验结果良好 公司有望成为减肥领域第三大投资对象 [1][2] - S&P Global Market Intelligence调查的分析师预测 公司今年收入不到200万美元 预计到2027年增至3800万美元 到2029年达7.29亿美元且首次实现盈利 [4] 投资建议 - 公司目前无营收和利润 若有药物上市将是重大成功 但从现在到盈利还有很多事要顺利推进 3期试验若失败情况可能迅速恶化 [3][5] - 公司股票目前是投机性股票 若要购买应少量并保持投资多元化 [5]